Partnership Announced from Title21 and Germfree to Innovate Decentralized Manufacturing Strategies
24 October 2023
Automation & Digitisation
Collaborations, Mergers & Acquisitions
The announcement of the partnership between Title21 Health Solutions and Germfree Labs hints at another product launch in the pipeline, while revolutionizing decentralized manufacturing and reducing time-to-market for cell and gene therapies.
Title21 and Germfree have today announced a partnership, introducing a mobile manufacturing platform, powered by Title21’s proprietary digital operating system (OS).
The partnership aims to address complexities associated with traditional centralized manufacturing models, reducing the impact of manufacturing bottlenecks to streamline access to cell and gene therapies and reduce the time-to-market.
Through the innovative decentralized model, the collaboration aims to realize a future whereby life-saving therapies transcend geographical boundaries, thus improving access regardless of location or circumstance.
“We are thrilled to join forces with Title21 Health Solutions in our mission to revolutionize cell and gene therapy manufacturing. Our commitment to state-of-the-art facility infrastructure aligns with Title21’s OS expertise, enabling decentralized manufacturing to reduce therapy costs and expand access,” explained Carol Houts, Chief Strategy Officer of Germfree Labs.
“At Title21 Health Solutions, we’ve always focused on delivering innovation and ensuring quality and regulatory compliance. Partnering with Germfree Labs allows us to extend our impact in the cell and gene therapy space. Together, we are building the future of patient-centred healthcare,” added Lynn Fischer, CEO of Title21 Health Solutions.
Both Carol and Lynn were joined by Najib Rehman, Digital Automation Lead at ATMPS, to discuss the intricacies of ‘Distributed and Point-of-Care Manufacturing – Pharmaceutical QMS Essentials Digital Systems’ at Advanced Therapies Week last year.
To watch the full series, ‘Delivering on the Promise of Cell and Gene Therapy Distributed and Point-of-Care Manufacturing’ hosted by Germfree, click here >>
As the two companies partner to launch a significant milestone in cell and gene therapy manufacturing through decentralized production, we’re looking forward to hearing more about subsequent product launches from the partnership.
Source: Title21 press release, received via email; featured image supplied and published with permission from Germfree.
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to email@example.com.
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.